abstract |
The invention relates to inhibitors of the transcription factor IRF-1, the use thereof as a therapeutical agent and to the use thereof for the prevention or the therapy of cardiovascular complications such as restenosis following percutaneous angioplasty or stenosis of venous bypasses, chronic (transplant arteriosclerosis or vasculopathy) or acute graft rejection, graft versus host disease (GVHD), immunological hypersensitivities (allergies), especially asthma bronchiale and atopic dermatitis, chronic recurrent inflammatory diseases, especially colitis ulcerosa and Crohn's disease, psoriasis and sarcoidosis, as well as autoimmune diseases, especially diabetes mellitus, multiple sclerosis, collagenoses (for example systemic lupus erythematosus), rheumatoid arthritis and vasculitides. |